

No.31026/16/2020-Policy
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals

Janpath Bhawan, New Delhi

Dated the 14th May, 2025

NOTICE

Subject: - Invitation of applications for the eligible products under the *Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country-reg.*

Subsequent to the decision of the Competent Authority applications are invited for below-mentioned unsubscribed or partially subscribed eligible products.

As per the decision taken, the conditions under the scheme, such as allocation according to available capacities, incentive ceiling in respect of products and limit of incentive up to the production tenure, i.e., up to FY 2027-28 for chemical synthesis products and up to FY 2028-29 for fermentation-based products, have to be complied with.

2. Further, applicants or their group companies, including subsidiaries who had applied earlier under the scheme for the said unsubscribed and partially subscribed products and were granted approval, but who subsequently withdrew from the scheme or whose approval was cancelled in line with clause 12.11 of the scheme guidelines or owing to non-performance, are not eligible to apply for the same eligible product.
3. Accordingly, applications are invited for the following eligible products: -

S. No.	Target segment	Name of eligible product	Minimum annual production capacity as per scheme guidelines (in MT)	Total available production capacity (in MT)	Maximum no. of applicants to be selected
1	Key Fermentation based KSMs/Drug Intermediates	Erythromycin Thiocyanate (TIOC)	800	1600	2
2	Fermentation based niche KSMs/Drug Intermediates/APIs	Neomycin	80	160	2
3	Fermentation based niche KSMs/Drug Intermediates/APIs	Gentamycin	40	80	2


14.05.2025

4	Fermentation based niche KSMs/Drug Intermediates/APIs	Clindamycin Base	60	120	2
5	Fermentation based niche KSMs/Drug Intermediates/APIs	Streptomycin	50	100	2
6	Fermentation based niche KSMs/Drug Intermediates/APIs	Tetracycline	200	400	2
7	Key Chemical Synthesis based KSMs/Drug Intermediates	2-Methyl (5) Nitro Imidazole (2MNI)	800	3200	4
8	Other Chemical Synthesis based KSMs/Drug Intermediates/APIs	Ciprofloxacin	150	600	4
9	Other Chemical Synthesis based KSMs/Drug Intermediates/APIs	Diclofenac Sodium	175	175	1
10	Key Chemical Synthesis based KSMs/Drug Intermediates	Dicyandiamide (DCDA)	8000	24000	3
11	Key Chemical Synthesis based KSMs/Drug Intermediates	1,1 Cyclohexane Diacetic Acid (CDA)	1500	1500	1

4. The eligible applicants may apply through online mode only (<https://plibulkdrugs.ifcilttd.com>) from 15.05.2025 to 14.06.2025. Detailed guidelines of the scheme and necessary corrigendum are available at <https://pharma-dept.gov.in/schemes>
5. The last date of receipt of complete application is 14.06.2025. Encl: As above


(Deshraj Yadav)

Under Secretary to the Government of India

Tel: 011-23383392

Email: US-PharmaSchemes@pharma-dept.gov.in

To

API manufacturers and eligible industries under the PLI scheme for bulk drugs.

Copy to: -

1. Shri Ravi Ranjan Mishra, Director-Advisory, IFCI Limited, IFCI Tower, 61, Nehru Place, New Delhi-110019, for further action to open the application window for 30 days from 15-05-2025.
2. Director, NIC, DoP- with a request to upload the same in the DoP website.



(Deshraj Yadav)

Under Secretary to the Government of India

Tel: 011-23383392

Email: US-PharmaSchemes@pharma-dept.gov.in